NVCR Stock Down -34% after 5-Day Loss Streak
NovoCure (NVCR) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -34% return. The company has lost about $421 Mil in value over the last 5 days, with its current market capitalization at about $1.3 Bil. The stock remains 63.2% below its value at the end of 2024. This compares with year-to-date returns of 8.2% for the S&P 500.
NVCR develops and markets Tumor Treating Fields devices for glioblastoma and other solid tumors, with ongoing product development targeting multiple cancer types. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Fear NVCR.
Comparing NVCR Stock Returns With The S&P 500
The following table summarizes the return for NVCR stock vs. the S&P 500 index over different periods, including the current streak:
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
- Comfort Systems USA Stock’s Winning Streak May Not Be Over Yet
| Return Period | NVCR | S&P 500 |
|---|---|---|
| 1D | -3.6% | -0.1% |
| 5D (Current Streak) | -33.6% | 0.1% |
| 1M (21D) | -38.4% | 2.5% |
| 3M (63D) | -40.0% | 14.4% |
| YTD 2025 | -63.2% | 8.2% |
| 2024 | 99.6% | 23.3% |
| 2023 | -79.6% | 24.2% |
| 2022 | -2.3% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: NVCR Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 22 S&P constituents with 3 days or more of consecutive gains and 121 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 83 |
| 4D | 4 | 15 |
| 5D | 1 | 20 |
| 6D | 5 | 3 |
| 7D or more | 4 | 0 |
| Total >=3 D | 22 | 121 |
Key Financials for NovoCure (NVCR)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $509.3 Mil | $605.2 Mil |
| Operating Income | $-232.9 Mil | $-170.5 Mil |
| Net Income | $-207.0 Mil | $-168.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $161.3 Mil | $155.0 Mil |
| Operating Income | $-63.3 Mil | $-37.9 Mil |
| Net Income | $-65.9 Mil | $-34.3 Mil |
The losing streak NVCR stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.